Spyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of Directors [Yahoo! Finance]
Spyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of Directors
Spyre Therapeutics, Inc. (NASDAQ: SYRE) had its price target raised by analysts at Wells Fargo & Company from $35.00 to $40.00. They now have an "overweight" rating on the stock.
Spyre Therapeutics, Inc. (NASDAQ: SYRE) had its price target raised by analysts at BTIG Research from $32.00 to $40.00. They now have a "buy" rating on the stock.
Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]